On Oct. 19, 2020, Atossa Therapeutics announced it had completed enrollment in its Phase 1 clinical study using Atossaﾒs proprietary drug candidate AT-301 administered by nasal spray. The Phase 1 study was a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.